TLDR QuantumScape posts $105.8M Q3 loss as rising R&D and scaling costs pressure financials Stock tumbles 12.5% to $13.58 as investors react to deepening quarterly losses Solid-state battery push drives heavy spending despite lower capex guidance Strong $1B liquidity cushions losses but delays path to profitability New Corning and Murata partnerships boost long-term solid-state battery [...] The post QuantumScape (QS) Stock Falls 12% as Q3 Loss and R&D Costs Weigh on Financials appeared first on Blockonomi.TLDR QuantumScape posts $105.8M Q3 loss as rising R&D and scaling costs pressure financials Stock tumbles 12.5% to $13.58 as investors react to deepening quarterly losses Solid-state battery push drives heavy spending despite lower capex guidance Strong $1B liquidity cushions losses but delays path to profitability New Corning and Murata partnerships boost long-term solid-state battery [...] The post QuantumScape (QS) Stock Falls 12% as Q3 Loss and R&D Costs Weigh on Financials appeared first on Blockonomi.

QuantumScape (QS) Stock Falls 12% as Q3 Loss and R&D Costs Weigh on Financials

2025/10/23 20:31
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

TLDR

  • QuantumScape posts $105.8M Q3 loss as rising R&D and scaling costs pressure financials
  • Stock tumbles 12.5% to $13.58 as investors react to deepening quarterly losses
  • Solid-state battery push drives heavy spending despite lower capex guidance
  • Strong $1B liquidity cushions losses but delays path to profitability
  • New Corning and Murata partnerships boost long-term solid-state battery ambitions

QuantumScape stock closed down 12.5% at $13.58 after reporting a $105.8 million net loss for the third quarter. The sell-off came despite the company narrowing its loss from $119.6 million in the same period last year.

Investors focused on the company’s continued cash burn rather than its operational improvements. The stock decline reflected concerns about the timeline to profitability.

The battery developer recorded $114.9 million in total operating expenses during Q3. This marked a decrease from $130.2 million a year earlier but remained substantial for a company in early-stage commercialization.


QS Stock Card
QuantumScape Corporation, QS

Research and development costs accounted for $92.1 million of the total. General and administrative expenses came in at $22.9 million for the quarter.

QuantumScape’s adjusted EBITDA loss reached $61.4 million in Q3. The company pointed to equipment investments and ecosystem partnerships as major expense drivers.

The negative operating performance continued to pressure investor sentiment. Market participants appeared less patient with the prolonged path to commercialization.

Solid-State Battery Development Requires Heavy Investment

The company is pushing forward with its QSE-5 battery technology. QuantumScape shipped its most advanced cells to date, the Cobra-based QSE-5 B1, during the quarter.

These cells are being field tested in Ducati’s V21L racing motorcycle. The deployment marks a key step in real-world validation of the technology.

QuantumScape is installing the Eagle Line at its San Jose headquarters. This highly automated pilot line aims to support higher-volume production capabilities.

Capital expenditures totaled $9.6 million for the quarter. The company lowered its full-year capex guidance to $30-$40 million due to adjusted timelines and improved efficiency.

The firm extended its commercial ecosystem through new collaborations with Corning and Murata. These partnerships focus on strengthening ceramic separator capabilities and supporting global battery demand.

Strong Balance Sheet Provides Extended Runway

QuantumScape ended Q3 with $1.0 billion in liquidity. This included $225.8 million in cash and equivalents plus $777.9 million in marketable securities.

Total current assets reached $1.02 billion. Management says this liquidity extends the company’s cash runway through 2030.

The company generated $285.5 million in financing inflows during the quarter. This included a $267.6 million equity raise completed before its shelf registration expired.

Total liabilities dropped to $127.5 million from $164.5 million in the prior year. Long-term liabilities decreased, though lease obligations and other liabilities remain on the books.

For the nine months ended September 30, QuantumScape recorded a $334.9 million net loss. This remains a critical concern for analysts tracking the company’s progress.

Revenue generation continues to lag behind expectations. The company is still transitioning from development to licensing and commercial-scale production.

The market reaction suggests investors may be reassessing their timeline expectations for breakeven. The combination of limited revenue and continued high expenses creates an uncertain outlook for near-term profitability.

QuantumScape shipped advanced battery cells and expanded its partnership network during Q3 while maintaining over $1 billion in liquidity to fund operations through 2030.

The post QuantumScape (QS) Stock Falls 12% as Q3 Loss and R&D Costs Weigh on Financials appeared first on Blockonomi.

Market Opportunity
DAR Open Network Logo
DAR Open Network Price(D)
$0.007108
$0.007108$0.007108
+0.21%
USD
DAR Open Network (D) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves

Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves

The post Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves appeared on BitcoinEthereumNews.com. The nation’s biggest health insurance companies will continue to cover vaccinations – including those against Covid-19 and seasonal flu – previously recommended by a federal advisory committee, America’s Health Insurance Plans said Wednesday, Sept. 17, 2025. In this photo is a free flu and Covid-19 vaccine shots available sign, CVS, Queens, New York. (Photo by: Lindsey Nicholson/Universal Images Group via Getty Images) UCG/Universal Images Group via Getty Images The nation’s biggest health insurance companies will continue to cover vaccinations – including those against Covid-19 and seasonal flu – previously recommended by a federal advisory committee. The announcement by America’s Health Insurance Plans (AHIP), which includes CVS Health’s Aetna, Humana, Cigna, Centene and an array of Blue Cross and Blue Shield plans as members, comes ahead of the first meeting of the reconstituted Advisory Committee on Immunization Practices, which now has new members chosen by U.S. Health and Human Services Secretary Robert F. Kennedy Jr., a vaccine critic. “Health plans are committed to maintaining and ensuring affordable access to vaccines,” AHIP said in a statement Wednesday. “Health plan coverage decisions for immunizations are grounded in each plan’s ongoing, rigorous review of scientific and clinical evidence, and continual evaluation of multiple sources of data.” The move by AHIP is good news for millions of Americans at a time of year when they flock to drugstores, pharmacies, physician’s offices and outpatient clinics to get their seasonal flu and Covid shots. Kennedy’s changes to U.S. vaccine policy have created confusion across the country over whether certain vaccines long covered by insurance would continue to be. AHIP has now provided some clarity for millions of Americans. “Health plans will continue to cover all ACIP-recommended immunizations that were recommended as of September 1, 2025, including updated formulations of the COVID-19 and influenza vaccines, with no cost-sharing…
Share
BitcoinEthereumNews2025/09/18 03:11
Standard Chartered’s Critical March Forecast Signals Monetary Policy Shift

Standard Chartered’s Critical March Forecast Signals Monetary Policy Shift

The post Standard Chartered’s Critical March Forecast Signals Monetary Policy Shift appeared on BitcoinEthereumNews.com. RBA Rate Hike: Standard Chartered’s Critical
Share
BitcoinEthereumNews2026/03/12 16:05
X1 EcoChain Partners with Symbiosis to Pioneer Cross-Chain Interoperability Ahead of Mainnet Launch

X1 EcoChain Partners with Symbiosis to Pioneer Cross-Chain Interoperability Ahead of Mainnet Launch

X1 EcoChain and Symbiosis are joining forces, making it possible to move assets seamlessly across 45-plus chains with mainnet launch right around the corner.
Share
Blockchainreporter2026/03/12 16:00